Clinical Trial Update: Syndecan-1 a Surrogate Marker for IBD

View source ↗

Summary

Completed clinical trial update evaluating Syndecan-1 as a surrogate biomarker for inflammatory bowel disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Snippet

Sponsor: Meir Medical Center | Conditions: Inflammatory Bowel Diseases | Status: COMPLETED